IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?. (3rd March 2016)

• Record Type: Journal Article
• Authors: Tomala, Jakub; Kovar, Marek
• Is Part Of: Oncoimmunology. Volume 5:Number 3(2016)
• Publication Date: 2016-03-03
• Subjects: Anti-IL-2 mAb -- cancer immunotherapy -- IL-2 -- immunocomplexes -- selective stimulatory activity; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1102829
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122 high populations, namely NK and memory CD8 + T cells. They also intermediately stimulate Treg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122 high populations. However, they potently and highly selectively stimulate CD25 + cells (i.e., Treg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models.